|
AU2004260884B2
(en)
*
|
2003-07-22 |
2009-11-19 |
Crucell Holland B.V. |
Binding molecules against SARS-coronavirus and uses thereof
|
|
US7622112B2
(en)
|
2003-12-05 |
2009-11-24 |
Jody Berry |
Anti-SARS monoclonal antibodies
|
|
SG159542A1
(en)
*
|
2004-11-11 |
2010-03-30 |
Crucell Holland Bv |
Compositions against sars-coronavirus and uses thereof
|
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US9200079B2
(en)
|
2004-11-12 |
2015-12-01 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
KR101616758B1
(ko)
|
2007-12-26 |
2016-04-29 |
젠코어 인코포레이티드 |
FcRn에 대한 변경된 결합성을 갖는 Fc 변이체
|
|
MY177098A
(en)
|
2013-08-09 |
2020-09-05 |
Astellas Pharma Inc |
Novel anti-human tslp receptor antibody
|
|
MX2017004103A
(es)
|
2014-10-01 |
2017-07-07 |
Medimmune Ltd |
Proteinas de union especificas para el receptor 1 de lipoproteinas de baja densidad oxidadas de tipo lectina (lox1) y sus usos.
|
|
CR20180365A
(es)
|
2015-12-16 |
2018-09-28 |
Amgen Inc |
PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
|
|
US20220089752A1
(en)
|
2019-01-14 |
2022-03-24 |
The Regents Of The University Of California |
Compositions and methods for modulating cellular internalization
|
|
AR120698A1
(es)
|
2019-12-09 |
2022-03-09 |
Ablynx Nv |
Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
|
|
US20250263466A1
(en)
|
2020-02-03 |
2025-08-21 |
Vir Biotechnology, Inc. |
Antibodies against sars-cov-2 and methods of using the same
|
|
WO2021156490A2
(en)
|
2020-02-06 |
2021-08-12 |
Vib Vzw |
Corona virus binders
|
|
HUE062777T2
(hu)
|
2020-02-26 |
2023-12-28 |
Vir Biotechnology Inc |
SARS-CoV-2 elleni antitestek
|
|
EP4121454A1
(en)
*
|
2020-03-19 |
2023-01-25 |
Imperial College Innovations Limited |
Coronavirus antibody
|
|
US11028167B1
(en)
|
2020-03-23 |
2021-06-08 |
Centivax, Inc. |
Anti-SARS-Cov-2 antibodies derived from 3bgf
|
|
CR20220552A
(es)
|
2020-04-02 |
2023-01-17 |
Regeneron Pharma |
Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
|
|
WO2021203053A1
(en)
|
2020-04-03 |
2021-10-07 |
Vir Biotechnology, Inc. |
Immunotherapy targeting a conserved region in sars coronaviruses
|
|
US20230348571A1
(en)
|
2020-04-06 |
2023-11-02 |
Vanderbilt University |
Cross-reactive coronavirus antibodies and uses thereof
|
|
US11192940B2
(en)
|
2020-04-10 |
2021-12-07 |
Adagio Therapeutics, Inc. |
Compounds specific to coronavirus S protein and uses thereof
|
|
BR112022020706A2
(pt)
|
2020-04-14 |
2022-11-29 |
Vir Biotechnology Inc |
Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
|
|
CN115461364B
(zh)
|
2020-04-28 |
2025-12-16 |
北京大学 |
一种抗新型冠状病毒的单克隆抗体及其应用
|
|
PH12022500020A1
(en)
|
2020-05-08 |
2024-05-06 |
Vir Biotechnology Inc |
Antibodies against sars-cov-2
|
|
WO2021247925A1
(en)
|
2020-06-03 |
2021-12-09 |
Vir Biotechnology, Inc. |
Structure-guided immunotherapy against sars-cov-2
|
|
CA3183373A1
(en)
|
2020-07-06 |
2022-01-13 |
Gevorg GRIGORYAN |
Antigen binding molecules targeting sars-cov-2
|
|
CA3183367A1
(en)
|
2020-07-06 |
2022-01-13 |
Gevorg GRIGORYAN |
Antigen binding molecules targeting sars-cov-2
|
|
WO2022015573A2
(en)
|
2020-07-13 |
2022-01-20 |
President And Fellows Of Harvard College |
Sars-cov-2 antigen-binding proteins and uses thereof
|
|
US20230058162A1
(en)
|
2020-07-27 |
2023-02-23 |
Igm Biosciences, Inc. |
Multimeric coronavirus binding molecules and uses thereof
|
|
WO2022046888A1
(en)
|
2020-08-25 |
2022-03-03 |
Target Discovery Merger Sub II, LLC |
Sars-cov-2 associated antibody compositions and methods of use
|
|
KR20230058434A
(ko)
|
2020-08-26 |
2023-05-03 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
SARS-CoV-2를 표적으로 하는 항원 결합 분자
|
|
KR20230127305A
(ko)
|
2020-12-29 |
2023-08-31 |
발-첨, 리미티드 파트너십 |
Covid-19에 대한 중화 단일클론 항체
|
|
US20240101646A1
(en)
|
2021-01-22 |
2024-03-28 |
Vanderbilt University |
Sars-cov-2 coronavirus antibodies and uses thereof
|
|
WO2022204202A1
(en)
|
2021-03-23 |
2022-09-29 |
Vir Biotechnology, Inc. |
Antibodies that bind to multiple sarbecoviruses
|
|
KR20240035758A
(ko)
|
2021-05-24 |
2024-03-18 |
비르 바이오테크놀로지, 인코포레이티드 |
조작된 폴리펩타이드
|
|
WO2022271863A1
(en)
|
2021-06-23 |
2022-12-29 |
Chan Zuckerberg Biohub, Inc. |
Coronavirus neutralizing compositions and associated methods
|
|
WO2023028603A2
(en)
|
2021-08-27 |
2023-03-02 |
Humabs Biomed Sa |
Engineered compositions
|
|
EP4147716A1
(en)
|
2021-09-10 |
2023-03-15 |
Samatva Research Corporation |
Anti-virus moiety immobilised in a matrix
|
|
IL316848A
(en)
|
2022-05-06 |
2025-01-01 |
Generate Biomedicines Inc |
Antigen-binding molecules targeting SARS-CoV-2
|